Quelling HIV: Enduring Antiretroviral Potency Amidst Initial Viremia and Its Absence

Title

Quelling HIV: Enduring Antiretroviral Potency Amidst Initial Viremia and Its Absence

Author

1. Lulu Adam, Student, Kilimanjaro Christian Medical University College, Tanzania
2. Walter Tenga, Lecturer, Kilimanjaro Christian Medical University College, Tanzania

Abstract

When it comes to viremia, or measurable viral levels in the bloodstream, the Human Immunodeficiency Virus (HIV) remains a major concern for world health. Despite the revolutionary impact of antiretroviral medication (ART), obstacles to adherence, viral reservoirs, and resistant virus strains continue to pose a threat to HIV treatment. Whether or not initial viremia is present, this article investigates the long-term efficacy of antiretroviral therapy. Our research delves at the inner workings of the virus, how long-acting antiretroviral therapy (ART) affects patients, and possible approaches to attaining long-term viral suppression. Examining the current literature critically reveals new information on viral reservoirs, medicines that improve adherence, and changing treatment paradigms.

Keywords

Conclusion

Long-acting antiretroviral therapy (LA-ART) has emerged as a promising strategy to address persistent viremia and adherence-related challenges in HIV treatment. By offering sustained drug release through injectable formulations, LA-ART reduces reliance on daily medication, improving adherence and long-term viral suppression. However, challenges such as drug resistance, missed doses, and accessibility in resource-limited settings must be carefully managed. Research has demonstrated that cabotegravir and rilpivirine effectively maintain virologic control, yet continued monitoring is essential to prevent resistance development. Expanding patient access to LA-ART requires robust healthcare infrastructure, community-based administration, and contingency plans for missed injections. Future investigations should focus on optimizing LA-ART for treatment-naïve individuals and those with persistent viremia. Addressing viral reservoirs remains crucial for achieving complete HIV eradication. Integrating innovative treatment strategies alongside traditional ART will be key to ensuring long-term disease control. With continued advancements, LA-ART has the potential to revolutionize HIV management and improve patient outcomes worldwide.

Author Contrubution

The author takes full responsibility for the entire study process, including design, data collection, analysis, and manuscript writing.

Funding

This study did not receive specific financial support from funding agencies in the public, commercial, or non-profit sectors.

Conflict of Interest

No conflicts of interest are reported by the authors.

Data Sharing Statement

Data sharing is not part of this study.

Software And Tools Use

This article does not include any software or tools usage information.

Acknowledgements

I appreciate the assistance and expertise provided by everyone involved in this research and manuscript, and the valuable comments from peer reviewers.